ERAXIS Safety Information
Important Safety Information
Abnormalities in LFTs have been observed with ERAXIS. Clinically significant hepatic
abnormalities have occurred in some patients with serious underlying medical conditions
who were receiving multiple medications concomitantly with ERAXIS. Isolated cases
of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have
been reported, but a causal relationship with ERAXIS has not been established. Patients
who develop abnormal LFTs during ERAXIS therapy should be monitored for evidence
of worsening hepatic function and evaluated for risk/benefit of continuing ERAXIS
therapy.
Possible histamine-mediated symptoms have been reported with ERAXIS, including rash,
urticaria, flushing, pruritus, dyspnea, and hypotension. These events are infrequent
when the rate of infusion does not exceed 1.1 mg/min.
In the treatment of candidemia, the most common treatment-related AEs included diarrhea
(3.1%), hypokalemia (3.1%), and elevated ALT (2.3%).